La Cuisine Espace MicroCaps - Discussions ouvertes


#1182

Nouvel article intéressant sur le blogue de Robin Speziale: Top 5 Investment Ideas From CANTECH 2019


#1183

Addition de smart money chez Well Health!

WELL Health Announces $2.7M Non-Brokered Private Placement Led by Mr. Li Ka-shing and WELL Management

02/19/2019 1:07:00 PM

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER and HONG KONG, Feb. 19, 2019 /CNW/ - WELL Health Technologies Corp. (TSX.V: WELL) (the " Company " or " WELL "), a company focused on consolidating and modernizing clinical and digital assets within the primary healthcare sector, is pleased to announce that it has come to terms for the sale of approximately $2.728M of its common shares in a private placement led by Hong Kong business leader Mr. Li Ka-shing and WELL’s own senior management team. The strategic investment by Mr. Li Ka-shing will be made in connection with a non-brokered private placement offering up to approximately 5.9M shares at a price of $0.46 per share which reflects the average prior 10-day closing price of WELL shares for gross proceeds of up to approximately $2.728M (the " Offering ").

Closing of the Offering is subject to a number of conditions, including receipt of any necessary corporate and regulatory approvals, including by the TSX Venture Exchange (the " Exchange ").

Through Horizons Ventures, Mr. Li Ka-shing has invested in some of the most iconic and innovative companies of the last decade including Facebook, Spotify, DeepMind, Siri, Impossible Foods, Chromadex and Modern Meadow.

Seven members of WELL’s management team will co-invest with Mr. Li Ka-shing in the amount of approximately $1.728M including Amir Javidan, WELL’s newly appointed Chief Operating Officer who will invest $1,000,000 and WELL’s Chairman and CEO, Hamed Shahbazi who will invest $500,000 as part of the Offering. In the case of WELL’s CEO, this investment when combined with previous investments he has made directly or indirectly in WELL’s stock cumulatively represents over $3.37M since February 2018 and well over $4M overall.

“We’re very pleased to demonstrate this big vote of confidence from WELL’s management team and Mr. Li Ka-shing,” said Hamed Shahbazi, Founder and CEO of WELL.

The net proceeds of the Offering are intended to be used in connection with the Company’s continued plans to consolidate and modernize primary healthcare facilities initially in Canada and then other markets. All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

Any participation by insiders in the Offering will be a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (" MI 61-101 ") but is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.


#1184

Est-ce que certains d’entre vous connaissez ou suivez/avez suivi l’entreprise Aurora Solar Technologies (ACU). L’action se transige maintenant à 0,05$ (prix du dernier placement privé de novembre 2018). En mai 2018, ils ont ouvert un bureau en Chine et récemment ont reçu une commande d’un manufacturier chinois. Croyez-vous que le moment serait opportun d’y faire son entrée? Que pensez-vous de ACU pour les prochaines années?


#1185

J’ai déjà été actionnaire dans le passé.

Technologie intéressante quoique un peu nichée. La dernière commande est de 150,000$-200,000$ seulement donc j’aimerais voir d’autres bonnes nouvelles avant de faire plus de recherches.


#1186

SRG.V Graphite inc , ca chauffe dans ce coin la , +14 vendredi close a 1.00$ et c’est 1,09 en ce moment pour acheter , peut etre plus haut demain matin


#1187

Bon lundi à tous! Je viens de publier un nouvel article sur le blogue. Il s’agit d’une collaboration avec Brandon Mackie de SmallCap Discoveries:

Le simple outil qu’il vous faut pour battre les marchés


#1188

SBM.V devrait dévoiler des résultats d’essais clinique d’ici 2 semaines. Aujourd’hui, un placement privé a été fermé (oversubscribed). Parmi les investisseurs, le CEO (près de 1M) et le CFO (350K).

Sirona Biochem closes $1.78-million private placement

Il semblerait que la direction ait déçu dans le passé (le produit est attendu depuis longtemps) et que les investisseurs commençaient à perdre patience.


#1189

Le QR de viemed…pas eu le temps de lire lol …regardait Gobal live @JustinTrudeau :open_mouth:

Viemed Healthcare Announces 2018 Record Financial Results

LAFAYETTE, La., Feb. 27, 2019 (GLOBE NEWSWIRE) – Viemed Healthcare, Inc. (VIEMF) (the “Company” or “Viemed”) (TSX:VMD.TO), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that its financial statements for the three months and year ended December 31, 2018 and accompanying Management’s Discussion & Analysis (MD&A) have been filed on SEDAR and are available at www.sedar.com.

Highlights are as follows (all dollar amounts are USD):

  • Revenues for the year ended December 31, 2018 were approximately $65.3 million and gross margin was $48.6 million, or 74%. Revenues and gross margin increased 39% and 40%, respectively, as compared to the year ended December 31, 2017. Revenues for the quarter ended December 31, 2018 grew sequentially by approximately 8% as compared to the quarter ended September 30, 2018.

  • The Company grew its ventilator patient count by approximately 35% as compared to prior year and 8% over third quarter 2018.

  • Capital expenditures totaled $14.5 million for the year ended December 31, 2018. The majority of the capital expenditures are once again to support the significant and continuous ventilator patient growth. Additionally, the Company has increased the number of ventilators it owns to more than 95% of its asset fleet.

  • Adjusted EBITDA for the year ended December 31, 2018 totaled approximately $17.2 million. The EBITDA was primarily reinvested in the aforementioned capital expenditures as the Company has consistently done in the prior quarters.

  • The Company has successfully been executing on its previously adopted Normal Course Issuer Bid whereby it purchased 410,703 of its common shares at an average price of $3.88 (USD) per share during the quarter ended December 31, 2018.

  • The Company had a working capital balance of $6 million as of December 31, 2018 and total long-term debt of $0.4 million. The Company has no borrowings against its $5 million line of credit as of December 31, 2018.

  • The Company expects to generate total revenues of approximately $20.0 - $20.5 million during the first quarter of 2019 and expects similar margins as the prior year. The mid-point of the revenue guidance represents a 44% increase over the quarter ended March 31, 2018 and a 10% increase over the quarter ended December 31, 2018.

“I am delighted with our team’s ability to execute in 2018 as we post yet another record-breaking quarter and year,” said Casey Hoyt, Viemed CEO. “Our world class clinicians are driven by improving quality of life and producing positive outcomes. Reporting these outcomes to our payers will become the cornerstone of our focus, as we aim to get our service to the 95% of patients in the country still in need of our care allowing for significant growth in future years.”

Conference Call Details

The Company will host a conference call to discuss Q4 2018 and full year 2018 results on Thursday, February 28, 2019 at 11:00 a.m. EST.

The call-in numbers for participants are:

US Toll Free: 1-800-263-0877

International Toll Free: 1-646-828-8143

Meeting ID Number: 1553280

We seek Safe Harbor.


#1190

Pour ceux qui suivent Enwave…

EnWave Logo.jpg

EnWave Announces 2019 First Quarter Consolidated Interim Financial Results and Appointment of Mr. Stephen Sanford to the Board of Directors

Email Print Friendly Share

February 28, 2019 08:30 ET | Source: EnWave Corporation

VANCOUVER, British Columbia, Feb. 28, 2019 (GLOBE NEWSWIRE) – EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today reported the Company’s consolidated interim financial results for the first quarter ended December 31, 2018.

Consolidated Financial Performance:

($ ‘000’s) Three months ended December 31,
2018 2017 Change
%

Revenues 7,806 4,519 73 %
Direct costs 4,769 3,093 54 %
Gross margin 3,037 1,426 113 %

Operating Expenses
General and administration 998 593 68 %
Sales and marketing 976 590 65 %
Research and development 341 272 25 %
2,315 1,455 59 %

Net loss for the period after taxes (15 ) (397 ) (96 %)
Loss per share – basic and diluted (0.00 ) (0.01 )

Adjusted EBITDA* 1,163 315 269 %

  • Adjusted EBITDA is a non-IFRS financial measure. Refer to the disclosure below regarding non-IFRS financial measures below and in the Company’s MD&A.

EnWave’s interim consolidated financial statements and MD&A are available on SEDAR at www.sedar.com and on the Company’s website www.enwave.net.

Key Financial Highlights for Q1 (expressed in ‘000s):

  • Reported the highest quarterly revenue ever for the Company in Q1 2019 of $7,806 compared to $4,519 for Q1 of 2018, an increase of $3,287. Royalty revenues for Q1 2019 increased to $251, compared with $203 for Q1 of 2018. Revenue growth was driven by increased sales and distribution of the Company’s Moon Cheese® product.

  • Achieved gross profit of $3,037 for Q1 2019 compared to $1,426 for Q1 2018, an increase of $1,611 or 113%. Gross margin as a percentage of revenue was 39% for Q1 2019 compared to 31% for Q1 2018.

  • Continued to strengthen the cash flow profile with Adjusted EBITDA(*) of $1,163 for Q1 2019 compared to $315 for Q1 2018, an increase of $848. The growth in positive EBITDA represents the Company’s continued ability to generate cash from its operations.

  • Reduced the consolidated net loss for the period after taxes to $15 for Q1 2019 compared to a net loss of $397 for Q1 2018, an improvement of $382 year-over-year.

  • Invested in selling and marketing with S&M expenses of $976 for Q1 2019 compared to $590 for Q1 2018, an increase of $386. S&M expenses increased as part of the strategy to invest in marketing for Moon Cheese® as well as selling activities that promote REVTM technology across the food and cannabis sectors.

  • Increased G&A and R&D expenses to $998 and $341 for Q1 2019, respectively, compared to $592 and $272 in Q1 2018. The Company added an experienced, full-time CEO for NutraDried to drive growth in the subsidiary business, and invested strategically in intellectual property to support our royalty licensing business model.

Significant Accomplishments:

  • Entered into a royalty-bearing commercial sub-license agreement with The Green Organic Dutchman (“TGOD”) and Tilray, Inc. (“Tilray”) granting TGOD non-exclusive rights to use EnWave’s technology for processing legalized cannabis in Canada. Received a purchase order from TGOD for a 60kW REVTM machine and robotic tray handling system.

  • Received a purchase order from Milne Microdried Inc. (“Milne”) for a 120kW REVTM processing line. The purchase order represents Milne’s third 120kW REVTM machine and significantly increases Milne’s total royalty-bearing processing capacity.

  • Signed a royalty-bearing commercial license agreement with Royal FrieslandCampina N.V. (“Friesland Campina”), one of Europe’s largest dairy companies. Friesland Campina will deploy REVTM technology to develop new products that fit the evolving consumer needs and taste preferences. Friesland Campina purchased a 10kW REVTM unit to initiate production.

  • Received a purchase order from Bare Foods Co. (“Bare Foods”), a leading American snack food company recently acquired by PepsiCo, for its third 10kW REVTM machine to expand commercial production of healthy fruit snack products.

  • Announced the commercial launch of Bonduelle Group’s (“Bonduelle”) InFlavor® dehydrofrozen vegetable product into the retail and food service channels. The Company extended Bonduelle’s exclusive rights to EnWave’s technology for dehydrofrozen vegetable products until September 30, 2019 in exchange for a milestone payment. Bonduelle must purchase a 400kW REVTM machine before September 30, 2019 in order to extend the term of its exclusive rights.

  • Signed a royalty bearing commercial sub-license agreement with Your Wasabi Farms (“YWF”) and Tilray granting YWF the non-exclusive rights to use EnWave’s technology to process cannabis plant material and industrial hemp.

  • Ended a commercial license agreement with Agropur Dairy Co-operative (“Agropur”). Agropur failed to purchase the large-scale REVTM machine that was required in order to extend its agreement with the Company.

  • Installed the first scaled-up Good Manufacturing Practices (“cGMP”) freeze REV® machine for Merck and passed site acceptance testing. The machine will be used by Merck for potential development of freeze REV®technology as a continuous dehydration alternative to lyophilization.

  • Expanded sales and distribution of Moon Cheese® with additional product rotations in a number of Costco divisions.

  • Doubled the Company’s production capacity of Moon Cheese® through the installation of a second 100kW nutraREV® machine and a 10kW REVTM machine. The expansion was facilitates continued sales growth of Moon Cheese® and positions for future projected demand in the consumer marketplace.

Appointment of Mr. Stephen Sanford to the Board of Directors:

The Company is pleased to announce that Mr. Stephen Sanford has been appointed to the Board of Directors as a new independent director. The addition of a highly experienced legal executive will further strengthen the diverse skillset of the Company’s Board of Directors.

Mr. Sanford is a seasoned legal professional with over 30 years of experience as an executive for a Fortune 500 company. He is the Senior Vice President and Managing General Counsel at Fluor Corporation (“Fluor”), a global engineering and construction company. Mr. Sanford has significant experience structuring major commercial transactions in a variety of legal systems around the world. In his role at Fluor, Mr. Sanford manages a team of legal professionals with a global footprint that addresses intellectual property matters, taxation, insurance and risk management matters. During his tenure at Fluor, Mr. Sanford has provided legal expertise and leadership during the structuring of billions of dollars in transactions.

Mr. Sanford obtained both his Bachelor’s Degree and Law Degree from Dalhousie University and holds an MBA from the University of Calgary.


#1191

Je viens de publier un nouvel article sur le blogue (que j’ai écrit moi-même):

Pourquoi le biais de conservatisme nuit à vos rendements

L’aspect pyschologique en investissement est sous-estimé je trouve, et c’est un sujet qui me fascine!


#1192

Bon article! Je viens justement de faire le ménage dans mes titres je m’améliore tranquillement à ce niveau là. J’ai lu une citation par rapport à ça tantôt:

“The stock doesn’t know you own it. You pay $10 for a stock, it goes to $8, and you think, “If it ever gets back to $10, I’ll sell it.” If it goes up to $20, you say, “I can sell half of it and take all my money out.” All those things are nuts.” W Buffett

Ça résume bien le tout je crois.


#1193

ECM.V Ecolomondo est une entreprise de technologie verte qui possède une technologie exclusive. Leur technologie permet la récupération de matière première de pneus usagés, substitut de noir de carbone, huile, gaz et acier. Aperçu de la technolgie Procédé de Décomposition Thermique

Ecolomondo est une entreprise d’ici et à bati une usine pilote Contrecœur, Québec. Elle semblait avoir de la difficulté pour lever du capital pour ses projets. Il y a d’ailleurs beaucoup d’actions en circulations. Cependant, hier une nouvelle est apparue sur le fil de presse Ecolomondo granted $32.1M in project financing from EDC

Peut-être le coup de pouce qu’elle avait besoin pour commencer à avoir des revenues.
site web : https://www.ecolomondo.com/?lang=fr

Divulgation : pas de position mais je la garde dans ma liste de à surveiller


#1194

Très bon article :wink: Comme le dit Munger, les biais psychologiques ont un effet multiplicateur lorsqu’il y en a plus d’un qui entre en jeu pour prendre 1 décision (lollapalooza effect). Il ne faut donc pas sous-estimé cet aspect.

Pour contrer mes propres biais, je trouve qu’avoir un processus d’investissement clair quant à l’achat, le suivi et la vente de titres est la meilleure méthode car ca oblige notre cerveau à emprunter un chemin de réflexion même si ce dernier souhaite inconsciemment l’éviter :stuck_out_tongue:


#1195

Je travail sur mon anglais mais en attendant ce mec m’aide beaucoup a comprendre la philosophie de la bourse , il publie touts les semaine ,


#1196

Je partage un article publié par Gerry Wimmer aujourd’hui sur son blog. Cette article s’adresse principalement aux investisseurs débutant dans le marché boursier.
Do simple math before you buy a small cap stock


#1197

Kraken Announces AquaPix® MINSAS-240 Sensor

03/06/2019 6:00:00 AM

ST. JOHN’S, Newfoundland , March 06, 2019 (GLOBE NEWSWIRE) – Kraken Robotics Inc. (TSX-V: PNG) (OTCQB: KRKNF) (“Kraken” or the “Company”), is pleased to announce that the Company has developed the AquaPix® MINSAS-240 Synthetic Aperture Sonar (SAS).

Karl Kenny, Kraken’s President & CEO said, "For demanding subsea survey missions in mine countermeasures, infrastructure monitoring and oil & gas exploration; time is of the essence. The sensor that gets the job done most effectively is one that combines ultra-high resolution imagery with an extremely high area coverage rate. Kraken’s latest development, the AquaPixâMINSAS-240 sensor, has been designed to advance the state-of-the-art in seabed mapping for both high-speed towed systems and Large Diameter Unmanned Underwater Vehicles (LDUUVs).”

The MINSAS-240 achieves an industry-leading Area Coverage Rate (ACR) of 5.3 km2/h with 3´3 cm image resolution and 6´6 cm bathymetry resolution across the entire swath. The incredibly high pixel density sets a new standard for seabed image quality. Kraken’s embedded real-time processor enables in-stride data analysis for faster decision making as all data is processed at the highest quality setting in real-time. The superior length of the MINSAS-240 receiver array allows for true full-aperture SAS processing even at tow speeds up to 20 knots without switching to a lower resolution imaging mode at high speed. The sensor is rated for operating depths of up to 6,000 metres.

In mine warfare, it is well known that the probability of detecting and classifying a target increases with improving image resolution. A similar principle applies for commercial seabed survey operations, where clear imagery is needed to show the health and integrity of subsea assets. High ACR is therefore only effective when the resolution of the data being collected satisfies the objectives of the mission. At lower resolution settings, multiples passes are required to detect and classify an object with confidence, reducing the effective rate of coverage. With its combination of speed, range, and resolution, Kraken’s MINSAS-240 achieves the world’s highest effective ACR, mapping the seabed in exceptional contrast, clarity and detail when every second counts.

Some applications for the MINSAS-240 Synthetic Aperture Sonar include:

Underwater Defence – MCM, ISR, REA
Hydrographic Survey
Marine Archaeology
Subsea Infrastructure Inspection – Oil and Gas, Offshore Wind, Tidal Energy
Environmental Assessment – Leak and Seep Detection, Offshore Asset Integrity
Seabed Survey – Search and Recovery

AquaPix® MINSAS-240 is now available and ready for integration on a wide variety of unmanned underwater platforms. For more information, please contact sales@krakenrobotics.com.


#1198

LD Micro organise une conférence virtuelle demain et mercredi. Il y a plusieurs compagnies intéressantes qui vont présenter (via webinaire).

Si vous cliquez sur l’onglet ‘‘Agenda’’ il y a la liste des compagnies avec l’horaire.

Personnellement, les compagnies qui m’intéressent le plus:

  • Medexus Pharmaceuticals (MDP.V)
  • AltiGen Communications (ATGN)
  • Xebec Adsorption (XBC.V)
  • Zynex (ZYXI)
  • Khiron Life Sciences (KHRN.V)
  • OneSoft Solutions (OSS.V)
  • Biomerica (BMRA)

#1199

@MMartin Je viens de m’inscrire. Si jamais tu en vois d’autres ça m’intéresse. Comme je travaille de soir c’est plus compliqué pour assister à des conférences mais ça c’est parfait pour moi.


#1200

Il y a une autre conférence virtuelle cette semaine. Elle a lieu jeudi et les entreprises suivantes vont faire une présentation:

MRI Interventions (MRIC)
Xpel inc. (DAP-U.V)
Sangoma Technologies (STC.V)
Park City Group (PCYG)
Where Food Comes From (WFCF)
Vertex Energy (VTNR)
IOU Financials (IOU.V)
Xebec Adsorbtion Inc (XBC.V)
Generation Next Franchise Brands (VEND)


#1201

Quelqu’un suit Verde Agritech (NPK.TO)? Ils possèdent et contrôlent plus de 500 000 acres au Brésil où se trouve un engrais et conditionneur de sol appelé glauconite ou Greensand. Le produit est vendu directement aux fermiers mais aussi sur amazon.

La compagnie vient de fermer un placement privé dans lequel le CEO a participé pour environ 32%. Le nouveau CFO et un directeur ont aussi participé. Historiquement, la compagnie a très peu dilué les actionnaires ce qui est assez surprenant pour un compagnie d’exploration/production. Environ 50M d’actions sur une base pleinement diluée suite à ce placement.

Placement with Insider Participation

BELO HORIZONTE, Brazil, March 13, 2019 (GLOBE NEWSWIRE) – Verde AgriTech Plc (TSX: NPK) (" Verde ” or the “ Company ”) is pleased to announce that it has closed its previously announced non-brokered private placement financing, issuing 2,820,114 units of securities (a “ Unit ”) at C$0.60 per Unit for total proceeds of C$1,693,067.20 (the “ Placement ”). Each Unit is comprised of one ordinary share of the Company (an “ Ordinary Share ”) and one-half of one Ordinary Share purchase warrant (a “ Warrant ”). Each whole Warrant is exercisable to purchase an Ordinary Share at an exercise price of C$1.00 until March 12, 2021. Verde previously announced that the Placement would be of a maximum of 1,666,666 Units, but increased the size of the Placement as a result of considerable demand.

The Placement included significant participation by a number of Verde’s officers and directors. President & CEO Cristiano Veloso, who already held 5,533,677 Ordinary Shares, purchased 912,416 Units; CFO Felipe Paolucci purchased 166,667 Units; and Director Michael St Aldwyn, who already held 32,340 Ordinary Shares, purchased 83,333 Units.

No commissions or compensation warrants have been paid or issued in connection with the Placement.

Commenting, President & CEO Cristiano Veloso, stated: “Verde will apply the raised funds as working capital to expedite its market growth. We are thankful to our new and existing shareholders for their continued support.”

divulgation : j’ai une petite position spéculative